MX9803419A - Extractos de cartilago de tiburon que tienen actividades anti-colagenolitica, anti-inflamatoria, anti-angiogenica y anti-tumoral, procesos para elaborarlos, metodos de utilizacion y composiciones de los mismos. - Google Patents

Extractos de cartilago de tiburon que tienen actividades anti-colagenolitica, anti-inflamatoria, anti-angiogenica y anti-tumoral, procesos para elaborarlos, metodos de utilizacion y composiciones de los mismos.

Info

Publication number
MX9803419A
MX9803419A MX9803419A MX9803419A MX9803419A MX 9803419 A MX9803419 A MX 9803419A MX 9803419 A MX9803419 A MX 9803419A MX 9803419 A MX9803419 A MX 9803419A MX 9803419 A MX9803419 A MX 9803419A
Authority
MX
Mexico
Prior art keywords
limitations
organizer
educational
disabilities
electrocution
Prior art date
Application number
MX9803419A
Other languages
English (en)
Inventor
Eric Dupont
Paul Brazeau
Christina Juneau
Daniel H Maes
Kenneth Marenus
Original Assignee
Aeterna Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Lab Inc filed Critical Aeterna Lab Inc
Publication of MX9803419A publication Critical patent/MX9803419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

La presente invencion se relaciona con extractos de cartílago y con un método para producir los mismos. Los extractos de cartílago de tiburon tienen actividades antigiogénica, anti-tumoral, anti-inflamatoria y anti-colagenolítica y se han obtenido por un proceso mejorado. El proceso comprende el paso de obtener un homogenado de cartílago en una solucion acuosa, este homogenado se separa en una fraccion solida (EXTRACTO SOLIDO) y en una fraccion líquida que se fracciona adicionalmente para obtener un EXTRACTO LIQUIDO, que tiene moléculas de un peso molecular comprendido entre 0 y 500 kDa. La composicion del extracto líquido se ha investigado por diferentes formas. La fraccionacion adicional de este extracto condujo a la caracterizacion preliminar de algunos de sus componentes activos. Devido a la multiplicidad de actividades biologicas del extracto líquido total, este puede usarse para tratar varias enfermedades o condiciones como aquellas que tienen componentes seleccionados del grupo que consiste de: proliferacion de tumor, angiogénesis, inflamacion y colagenolisis. Varias aplicaciones cosméticas que se basan en la capacidad del extremo líquido para mejorar las funciones de barrera de la piel también quedan dentro del alcance de esta invencion. Estos extractos no tienen efecto ofensivo sobre las funciones normales del cuerpo. Por lo tanto, estos extractos de cartílago de tiburon tiene un valor terapéutico muy prometedor. El proceso para la obtencion de los extractos de cartílago es simple y eficiente. Los productos inesperadamente valiosos que se obtienen por este proceso son, por lo tanto, una indicacion de un proceso nuevo y no obvio.
MX9803419A 1995-10-30 1998-04-30 Extractos de cartilago de tiburon que tienen actividades anti-colagenolitica, anti-inflamatoria, anti-angiogenica y anti-tumoral, procesos para elaborarlos, metodos de utilizacion y composiciones de los mismos. MX9803419A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/550,003 US6025334A (en) 1994-04-28 1995-10-30 Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof

Publications (1)

Publication Number Publication Date
MX9803419A true MX9803419A (es) 1998-10-31

Family

ID=24195326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803419A MX9803419A (es) 1995-10-30 1998-04-30 Extractos de cartilago de tiburon que tienen actividades anti-colagenolitica, anti-inflamatoria, anti-angiogenica y anti-tumoral, procesos para elaborarlos, metodos de utilizacion y composiciones de los mismos.

Country Status (28)

Country Link
US (1) US6025334A (es)
EP (1) EP0859622B1 (es)
JP (2) JPH11513990A (es)
KR (1) KR100296016B1 (es)
CN (1) CN1187060C (es)
AT (1) ATE230604T1 (es)
BG (1) BG63907B1 (es)
BR (1) BR9611507A (es)
CA (1) CA2236021C (es)
CO (1) CO4750839A1 (es)
CZ (1) CZ129398A3 (es)
DE (1) DE69625698T2 (es)
DK (1) DK0859622T3 (es)
ES (1) ES2190475T3 (es)
HK (1) HK1015683A1 (es)
HU (1) HU225490B1 (es)
IL (1) IL119030A (es)
IN (1) IN188198B (es)
IS (1) IS2017B (es)
MX (1) MX9803419A (es)
NO (1) NO981781L (es)
NZ (1) NZ313957A (es)
PL (1) PL187989B1 (es)
RO (1) RO118567B1 (es)
RU (1) RU2181292C2 (es)
TW (1) TW503108B (es)
WO (1) WO1997016197A1 (es)
ZA (1) ZA966726B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
GB9621630D0 (en) * 1996-10-17 1996-12-11 Kappa Pharmaceuticals Ltd Treatment of skin disorders
EP0842670A1 (en) * 1996-11-13 1998-05-20 Katsunari Nishihara Biomedical materials
CA2288269A1 (en) 1997-02-20 1998-08-27 Industrial Research Limited Angiogenesis inhibitors and activators from shark cartilage
IL131701A (en) * 1997-03-11 2005-03-20 Aeterna Zentaris Inc Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
AU8379098A (en) * 1997-07-11 1999-02-08 Cv Technologies Inc. A preparation derived from shark cartilage for treatment of diseases related to excessive phf or excessive intracellular calcium
JPH11171782A (ja) * 1997-12-03 1999-06-29 Kaoru Yamane 液体鮫軟骨の製造方法
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
US20020009501A1 (en) * 1998-07-23 2002-01-24 Eric Dupont Preparation of cartilage extracts using organic solvents
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
KR100355952B1 (ko) * 2000-03-15 2002-10-11 주식회사 코리아나화장품 상어 연골추출물과 비타민 케이 유도체를 함유하는 화장료조성물
AU2001242502A1 (en) * 2000-03-31 2001-10-15 Henkel Kommanditgesellschaft Auf Aktien Use of protease inhibitors in cosmetics and pharmacy
BR0114470A (pt) * 2000-12-20 2004-01-13 Ind Res Ltd Extrato de carne de tubarão
TWI233361B (en) * 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
AU2002325108A1 (en) * 2001-08-27 2003-03-10 Les Laboratoires Aeterna Inc. Serine protease inhibitor and processes for the preparation thereof
CA2476126A1 (en) * 2002-02-15 2003-08-21 Ocean Nutrition Canada Limited Shark cartilage extracts and use thereof for immunomodulation
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20070010430A1 (en) * 2003-03-20 2007-01-11 Hosokawa Micron Corparation Proteoglycan isolated from cartilaginous fish and process for producing the same
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US20050222687A1 (en) * 2004-04-02 2005-10-06 Gordana Vunjak-Novakovic Cartilage implant assembly and method for implantation
US20090291112A1 (en) * 2003-05-16 2009-11-26 Truncale Katherine G Allograft osteochondral plug combined with cartilage particle mixture
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
ES2223291B1 (es) * 2003-08-06 2006-03-16 Bioiberica, S.A. Nuevo uso terapeutico de condroitin sulfato.
EP2335650B1 (en) 2003-12-11 2012-10-03 Isto Technologies Inc. Particulate cartilage system
JP4390809B2 (ja) * 2004-01-07 2009-12-24 イーエルシー マネージメント エルエルシー 発毛遅延のための化粧品組成物及び方法
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US20050288796A1 (en) * 2004-06-23 2005-12-29 Hani Awad Native soft tissue matrix for therapeutic applications
US7837740B2 (en) * 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20080220044A1 (en) * 2007-03-06 2008-09-11 Semler Eric J Cancellous construct with support ring for repair of osteochondral defects
WO2006059236A2 (en) * 2004-11-16 2006-06-08 Aeterna Zentaris Inc. Method of using cartilage extract for increasing blood parameters
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
JP4875865B2 (ja) * 2005-08-17 2012-02-15 株式会社日本バリアフリー 変形性関節症の予防及び治療用ＮＴｘ値低減剤
US8480757B2 (en) 2005-08-26 2013-07-09 Zimmer, Inc. Implants and methods for repair, replacement and treatment of disease
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US7951782B2 (en) 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8435551B2 (en) * 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
EP2224884A2 (en) * 2007-12-05 2010-09-08 Musculoskeletal Transplant Foundation Cancellous bone implant for cartilage repair
CA2717725A1 (en) * 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
EP2262469A4 (en) * 2008-04-15 2013-12-04 Immanence Integrale Dermo Correction Inc SKIN CARE COMPOSITIONS AND METHODS OF USE
RU2592850C2 (ru) * 2011-01-19 2016-07-27 Хиросаки Юниверсити Способ крупномасштабного получения протеогликана
US9347081B2 (en) 2011-04-19 2016-05-24 Bioiberica, S.A. Cartilage product
ES2403804B1 (es) * 2011-09-21 2014-07-15 Bioib�Rica, S.A. Producto de cartílago.
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
RU2526825C1 (ru) * 2013-06-18 2014-08-27 Вера Геннадьевна Лихванцева Фармацевтическая антиангиогенная композиция для лечения заболеваний глаз
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN104877009B (zh) * 2015-05-11 2020-08-11 浙江海洋学院 一种赤魟软骨多肽类血管生成抑制因子
JP6929346B2 (ja) 2016-07-04 2021-09-01 カンステム バイオテック カンパニー リミテッド 軟骨無細胞破砕物及び幹細胞を含む軟骨分化促進用複合体及びその用途
KR102154976B1 (ko) * 2018-08-30 2020-09-11 전남대학교산학협력단 구내염 치료용 하이드로겔
KR102369902B1 (ko) * 2021-04-23 2022-03-02 이수한 전 처리된 캐비아가 함유된 철갑상어 진액 및 그 제조 방법
KR20220166032A (ko) 2021-06-09 2022-12-16 아스코코리아 주식회사 조립식 캠핑 테이블

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3478146A (en) * 1965-02-26 1969-11-11 Leslie L Balassa Wound-healing cartilage powder extracting process
US4042457A (en) * 1975-11-10 1977-08-16 Rush-Presbyterian-St. Luke's Medical Center Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor
US4822607A (en) * 1976-10-29 1989-04-18 Lescarden Ltd. Anti-tumor agent and method
US4243582A (en) * 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
US4350682A (en) * 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
US4356261A (en) * 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4656137A (en) * 1985-09-12 1987-04-07 Lescarden Inc Method of processing animal cartilage
US4749522A (en) * 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
WO1994012510A1 (en) * 1992-11-30 1994-06-09 Lane I William Processing shark cartilage
NZ511762A (en) * 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US5618925A (en) * 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
JPH0870822A (ja) * 1994-09-01 1996-03-19 Makoma Kk カプセル入り食品及びその製造法
CZ292627B6 (cs) * 1995-02-03 2003-11-12 Les Laboratoires Aeterna Inc. Léčivo pro léčení nemocí nebo poruch majících složku kolagenolytickou nebo zánětlivou

Also Published As

Publication number Publication date
NO981781L (no) 1998-06-19
ATE230604T1 (de) 2003-01-15
IS4728A (is) 1998-04-29
CA2236021C (en) 2002-07-30
DE69625698T2 (de) 2003-10-16
RO118567B1 (ro) 2003-07-30
CN1206348A (zh) 1999-01-27
ZA966726B (en) 1997-02-18
JPH11513990A (ja) 1999-11-30
EP0859622B1 (en) 2003-01-08
HUP9802604A2 (hu) 1999-10-28
EP0859622A1 (en) 1998-08-26
CZ129398A3 (cs) 1998-12-16
WO1997016197A1 (en) 1997-05-09
HK1015683A1 (en) 1999-10-22
DE69625698D1 (de) 2003-02-13
PL187989B1 (pl) 2004-11-30
IN188198B (es) 2002-08-31
NO981781D0 (no) 1998-04-21
JP2003246740A (ja) 2003-09-02
BR9611507A (pt) 1999-12-28
TW503108B (en) 2002-09-21
RU2181292C2 (ru) 2002-04-20
PL326888A1 (en) 1998-10-26
CA2236021A1 (en) 1997-05-09
HUP9802604A3 (en) 2001-06-28
CO4750839A1 (es) 1999-03-31
BG63907B1 (bg) 2003-06-30
CN1187060C (zh) 2005-02-02
BG102419A (en) 1999-01-29
US6025334A (en) 2000-02-15
KR100296016B1 (ko) 2001-10-26
IL119030A (en) 2000-08-13
KR19990067245A (ko) 1999-08-16
HU225490B1 (en) 2006-12-28
DK0859622T3 (da) 2003-05-05
IL119030A0 (en) 1996-11-14
ES2190475T3 (es) 2003-08-01
IS2017B (is) 2005-06-15
NZ313957A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
MX9803419A (es) Extractos de cartilago de tiburon que tienen actividades anti-colagenolitica, anti-inflamatoria, anti-angiogenica y anti-tumoral, procesos para elaborarlos, metodos de utilizacion y composiciones de los mismos.
Zurif et al. Dyslexia in relation to cerebral dominance and temporal analysis
Lehr A vector derivation useful in impedance plethysmographic field calculations
H. Logie et al. The inner eye and the inner scribe of visuo-spatial working memory: Evidence from developmental fractionation
ATE270125T1 (de) Magnetischer stimulator zur reizung peripherer nerven
Kephart Learning Disability: An Educational Adventure. The 1967 Kappa Delta Pi Lecture.
Slavin Cooperative learning: Engineering social psychology in the classroom.
Galin Educating both halves of the brain
Zach et al. How adequate is the concept of perceptual deficit for education?
Reynolds et al. Elementary teachers' attitudes toward mainstreaming educable mentally retarded students
Lyon et al. Educational validation studies with subtypes of learning-disabled readers.
Halliday Psychological self-help books--How dangerous are they?
Martmer The child with a handicap
CA2175511A1 (en) Educational and life skills organizer/memory aid
Dennis et al. Current trends in psychological theory.
Walker et al. Correlation of sensory integration and praxis test scores with metropolitan achievement test scores in normal children
Frey et al. Selective attention and the judgment of temporal order
JPS6417086A (en) Vehicle with education and lecture apparatus
Stover et al. A demonstration technique for interpreting perceptual-motor neurological difficulties to parents and teachers
Blanton et al. Cognitive retraining therapies for neurologically impaired patients.
Bassuk et al. Developing and assessing a training program in prehospital care of behavioral emergencies
McIntyre et al. The effectiveness of various types of teacher directions with students labeled behavior disordered
Skaarbrevik Clients of the School Psychological Service in a Norwegian Community
Weir The computer as a creative educational tool
Wulf et al. A Comparison of Danish and US Strategies to Provide for Children with Special Needs